NL-OMON31737
Withdrawn
Phase 2
A Phase I/II study to determine the safety and efficacy of a combination of anti-CD3 & anti-CD7 ricin A immunotoxins for treating steroid-resistant acute graft-versus-host disease. - IT-combination for aGVHD
Henogen S.A.0 sites12 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Immuunsysteemaandoeningen: acute omgekeerde afstotingsziekte
- Sponsor
- Henogen S.A.
- Enrollment
- 12
- Status
- Withdrawn
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients suffering from severe acute GVHD (Grade II\-IV) that is progressing after 3 days, or non\-improving after 5 days, of prednisolone at 2 mg/kg a day.
Exclusion Criteria
- •Patients receiving concomitant investigational therapeutics for acute GVHD, including agents used for GVHD prophylaxis, at the time of enrollment.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A Phase I/II study to determine the safety and efficacy of a combination of anti-CD3 & anti-CD7 ricin A immunotoxins (T-Guard) for treating steroid-resistant acute graft-versus-host disease.NL-OMON44132Xenikos BV10
Recruiting
Phase 1
Injection of Bromelain and Acetylcysteine in combination into recurrent mucinous tumour or pseudomyxoma peritonei: a phase I/II studypseudomyxoma peritoneirecurrent pseudomyxoma peritoneiperitoneal diseaselow grade appendix tumourCancer - Other cancer typesACTRN12617001612303Professor David Morris60
Recruiting
Phase 1
A Phase I/II study to assess the safety and efficacy of full-spectrum medicinal cannabis plant extract 0.08% THC (NTI164) in the treatment of Rett syndrome (RTT)Rett SyndromeNeurological - Neurodegenerative diseasesACTRN12623000563662Fenix Innovation Group14
Active, Not Recruiting
Phase 1
Phase I/II Study to Evaluate the Safety and Efficacy of JB-101(Induced T Cell With Suppressing Functions), to Induce Operational Tolerance in Living Donor Liver Transplantation.JPRN-jRCT2073200067chida Koichiro10
Active, Not Recruiting
Phase 1
Phase I/II Study of MK-3475 in Combination with Trametinib and Dabrafenibadvanced or metastatic melanoma - all parts of the trialadvanced (unresectable and/or metastatic) solid tumours - Parts 4 and 5MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-000681-55-DKMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.190